Back to top

Image: Bigstock

5 Stocks to Buy as New Analysts Show Interest

Read MoreHide Full Article

Coverage initiation by analyst(s) on a stock inevitably leads to increased investor enthusiasm. This is because investors assume that there is something in the stock that has attracted analyst attention. In other words, they assume that the company coming under the microscope definitely has some value.

Why do analysts initiate coverage? Of course, stocks are not randomly picked to cover. A new coverage on a stock is usually the result of a promising future envisioned by the analyst(s). At times, increased investors’ focus on a stock motivates analysts to take a closer look at it. After all, who doesn’t love to produce something that is already in demand?

Importantly, average change in broker recommendation is always preferred over a single recommendation change.

Analyst Coverage & Price Movement

Interestingly, price movement is generally a function of the recommendations from new analysts. Stocks typically see an upward price movement on new analyst coverage compared to what they witness with a rating upgrade under an existing coverage. Positive recommendations — Buy and Strong Buy — generally lead to a significantly positive price reaction than Hold recommendations. On the contrary, analysts hardly initiate coverage with a Strong Sell or Sell recommendation.

Now, if an analyst issues a new recommendation on a company that has limited or no existing coverage, investors take notice of the stock. Also, any new information attracts portfolio managers to build a position in the stock.

So, it’s a good strategy to bet on stocks that have seen increased analyst coverage over the last few weeks.

Screening Criteria

Number of Broker Ratings now greater than the Number of Broker Ratings four weeks ago (This will shortlist stocks that have recent new coverage).

Average Broker Rating less than Average Broker Rating four weeks ago ('Less than' means 'better than' four weeks ago).

Increased analyst coverage and improving average rating are the primary criteria of this strategy but one should consider other relevant parameters to make the strategy foolproof.

Here are the other screening parameters:

Price greater than or equal to $5 (as a stock below $5 will not likely create significant interest for most investors).

Average Daily Volume greater than or equal to 100,000 shares (if volume isn’t enough, it will not attract individual investors).

Here are five of the 11 stocks that passed the screen:

Safeguard Scientifics, Inc. provides capital and relevant expertise to drive technology-driven businesses. While Safeguard has underperformed the industry so far this year, this Zacks Rank #2 (Buy) company’s loss estimates have narrowed down to $1.39 from $2.66 over the past 30 days for 2018. The company’s bottom line is expected to witness around 68% year-over-year growth in the year.

Exantas Capital Corp. , a real estate investment trust, has gained more than 23% this year, while its industry has declined 2%. The stock carries a Zacks Rank #2 and its estimates have moved 29.7% north for 2018 over the past 30 days. Earnings for the company are expected to rise 162.3% in 2018.

Champions Oncology, Inc. (CSBR - Free Report) , a company engaged in the development of advanced technology solutions to personalize the advancement and use of oncology drugs, has seen its shares climb 106.4% this year, faring much better than the industry’s 1.3% increase. This Zacks Rank #3 (Hold) stock has seen its earnings estimates move up 25% for 2018 over the last 60 days. Earnings for the company are expected to rise 200% in the current year. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Stars Group Inc. is a technology-based products and services provider to gaming and interactive entertainment industries in Canada and internationally. Shares of the company have gained 37.1% year to date, while its industry saw a 12.1% decline. The Zacks Consensus Estimate for current-year earnings has moved up 2% over the last 30 days. Earnings for the company are expected to grow 11.1% in 2018.

GDS Holdings Limited (GDS - Free Report) , a information technology service provider, has gained 23.4% year to date, outperforming the 14.1% increase of its industry. This Zacks Rank #3 stock’s loss estimates have narrowed to 36 cents from 41 cents for the current year over the last 30 days. The bottom line for the company is expected to grow 29.4% this year.

You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge.

The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.

Click here to sign up for a free trial to the Research Wizard today.

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

Disclosure: Performance information for Zacks’ portfolios and strategies are available at: https://www.zacks.com/performance

Zacks Restaurant Recommendations: In addition to dining at these special places, you can feast on their stock shares. A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector. Download it free »


Unique Zacks Analysis of Your Chosen Ticker


Pick one free report - opportunity may be withdrawn at any time


Champions Oncology, Inc. (CSBR) - $25 value - yours FREE >>

GDS Holdings (GDS) - $25 value - yours FREE >>

Published in